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Available online 2 September 2016Background: Transforming growth factor-β1 (TGF-β1) reportedly acts as a tumor suppressor in tumorigenesis.
However, little is knownas to howTGF-β1 concentrations change prior to the development of hepatocellular car-
cinoma (HCC) in humans. We examined the association between the serum TGF-β1 concentrations and death
from HCC to determine whether the serum TGF-β1 can be a predictor of incident HCC.
Methods:Weconducted a nested case-controlled study of participants in the Japan Collaborative Cohort Study for
Evaluation of Cancer Risk.Weused a conditional logistic regression analysis to estimate the adjusted relative risks
(aRRs) of death from HCC according to the serum TGF-β1 concentrations among 1940 participants including 83
patients with HCC and 1857 controls matched for age, sex, and hepatitis C virus (HCV)-antibody seropositivity.
Findings:When serum TGF-β1wasmodelled as a continuous variable, the aRR of death fromHCC associatedwith
a decrement of 7.9 ng/mL (one standard deviation) in the serum TGF-β1 concentrations was 2.3 (95% CI 1.7–3.0,
P b 0.001) for all the subjects. The area under the receiver operating characteristic curve for the serum TGF-β1
concentrations was 0.78 (P b 0.05).
Interpretation: Our ﬁnding suggests that TGF-β1 serves as a predictor for HCC.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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TGF-β11. Introduction
Transforming growth factor-β1 (TGF-β1) is a member of the TGF-β
family, which regulates many cell functions such as differentiation, im-
mune homeostasis, and carcinogenesis (Massagué et al., 2000). Report-
edly, TGF-β1 has a dual nature–it acts as a tumor suppressor at early-
stage carcinogenesis but promotes invasion and metastasis at later
stages (Derynck et al., 2001; Ikushima and Miyazono, 2010; Lin et al.,
2015). However, little is known as to how TGF-β1 concentrations
change prior to the development of hepatocellular carcinoma (HCC) in
humans.
HCC is the third most common cause of cancer death worldwide
(Ferlay et al., 2010). HCC has a poor prognosis, with an overall ﬁve-
yearmortality rate of N88% (Mittal and El-Serag, 2013). Current curativeent of Social Medicine, Osaka
uita-shi, Osaka 565-0871, Japan.
. This is an open access article undertreatments such as surgical resection are limited to early-stage HCC;
however, HCC is difﬁcult to diagnose early enough to perform a radical
treatment (El-Serag et al., 2008; Imamura et al., 2003). Although several
biomarkers have been proposed for early detection of HCC, such as
alpha-fetoprotein (AFP), Lens culinaris agglutinin reactive AFP (AFP-
L3), des-γ-carboxy prothrombin (DCP), glypican-3 (GPC3), and Golgi
protein 73 (GP73) (Malaguarnera et al., 2010; Yamamoto et al., 2010),
nobiomarker has been known to become elevated evenbefore develop-
ment of HCC so far. Discovery of such biomarker iswarranted to identify
patients who are at higher risk of developingHCC. In general, to the best
of our knowledge, there has been no serum biomarker that can predict
the development ofmalignancy even beforemalignant cells are formed.
As TGF-β1 is shown to function as a tumor suppressor when cancer
emerges, TGF-β1 would be a potential candidate as a predictor for
HCC. Thus far, no prospective cohort study has assessed the relationship
between the serum TGF-β1 concentrations and incidence of HCC in the
general population.
Therefore, in the current nested case-controlled study, we examined
prospective association between serum TGF-β1 concentrations and thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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a predictor of incident HCC.
2. Materials and Methods
2.1. Study Population and Serum Samples
We conducted a nested case-controlled study within the Japan Col-
laborative Cohort Study (the JACC Study) for Evaluation of Cancer
Risk. The baseline survey for this study was performed in 1988–1990.
A total of 110,585 participants (46,395 men and 64,190 women) aged
40–79 years and living in 45 areas across Japan responded to self-ad-
ministered questionnaires regarding their lifestyles, such as their
smoking and alcohol drinking status, and their medical histories of
major diseases, including liver diseases and cancer. The JACC Study
was approved by the Ethical Boards at the Osaka University School of
Medicine and the Nagoya University School of Medicine, and partici-
pants' informed consent was obtained.
Participants underwent municipal health screening examinations
where peripheral blood samples were collected from 39,242 individ-
uals. Serum from these samples was separated and stored at−80 °C.
This has been proven to be a reliable method to maintain TGF-β1 con-
centrations because there was no signiﬁcant difference in measured
values of TGF-β1 between newly collected serum and frozen specimens
that had been stored for nine years (Ito et al., 2005; Tamakoshi et al.,
2009).
2.2. Case Ascertainment
We followed the subjects from the date of the baseline survey
through December 31, 1999 to obtain information on the cause of
death from death certiﬁcates provided by theMinistry of Health, Labour
and Welfare in Japan. We identiﬁed liver cancer according to the Inter-
national Classiﬁcation of Diseases, tenth revision (ICD-10) code C22.0–
22.9.
2.3. Surveillance
For the mortality surveillance, we reviewed death certiﬁcates and
classiﬁed the underlying causes of death coded for the National Vital
Statistics according to ICD-10. All deaths that occurred in the cohort
were ascertained by death certiﬁcates from public health centers, ex-
cept for participants who died after moving from their original areas,
which became censored cases.
2.4. Measurements of Serum Constituents
Wemeasured the constituent serum concentrations, such as TGF-β1,
among all the cancer patients as well as their healthy controls. The
serum TGF-β1 concentrations were measured using a quantitative
sandwich enzyme immunoassay, with a commercially available kit
(Quantikine; R&D Systems Inc. Minneapolis, MN, USA) at SRL Laborato-
ry (Hachioji, Tokyo, Japan) in 1999 (Ito et al., 2005; Tamakoshi et al.,
2009).
2.5. Statistical Analysis
The statistical analyses were based on the mortality during the fol-
low-upperiod (1989–1999). Differences in themean values of the base-
line characteristics between the HCC and control groups were tested
using the Student t-test. We examined the association between serum
TGF-β1 concentrations and mortality from HCC.
Age-adjusted and multivariate-adjusted relative risks (aRRs) and
their 95% conﬁdence intervals (CIs) of HCC-related mortality stratiﬁed
by hepatitis C virus (HCV)-positivity were calculated after adjustments
for age and potential confounding factors using a conditional logisticregression analysis. The confounding variables included age (years),
smoking (never, former or current smokers), drinking habits (never,
former, or current drinkers who consumed b20 g or ≥20 g of ethanol
per day), and history of diabetes mellitus or liver disease. These factors
are known to increase the risk of HCC (Forner et al., 2012). Although
body-mass index N40 is known to be a risk factor for mortality
(Forner et al., 2012), we did not adjust for body-mass index because
no participant had body-mass index N40 in our population. We per-
formed HCV tests in the current study because about 80% of all HCC
cases in Japan are thought to be associated with HCV infection (El-
Serag et al., 2001).
In order to exclude the possibility of undetected HCC at baseline
when the TGF-β1 concentrations were measured, we performed a sen-
sitivity analysis limiting the patient populationwho survived for at least
ﬁve years after starting follow-up given amedian ﬁve-year survival rate
of 6% in patients with HCC (Siegel and Massagué, 2003).
For the trend analysis, we calculated aRRs per one standard devia-
tion (SD) decrease in the TGF-β1 concentrations as a continuous vari-
able. Receiver operating characteristics (ROC) curves were constructed
to assess the areas under the curve (AUC) and the 95% CI.We calculated
the cut-off point by the Euclidean distance method. All the analyses
were performed using SAS statistical package version 9.2 (SAS Institute
Inc., Cary, NC). A two-sided P-value of b0.05was considered statistically
signiﬁcant.
3. Results
3.1. Description of the Study Population
Every participant in the study was followed for ten years. During the
follow-up period, 550 deaths from liver cancer were observed. Baseline
serum samples had been collected from 120 out of these 550 subjects.
We excluded 24 cases that did not have a C22.0 code or that had insuf-
ﬁcient data regardingHCV positivity. Out of the 96 eligible patients who
had died fromHCC (ICD-10 codeC22.0) as of the endpoint of the current
study, 13 patients did not have serum data for TGF-β1. Among the re-
maining 83 patients, 58 (70%) tested positive for HCV and 25 (30%) test-
ed negative. As potential controls, serum samples from 10,574 subjects
living in the same geographical areas as the caseswere also screened for
HCV infection. After excluding those with missing TGF-β1 data, 491
(9%) of the controls were HCV-positive, and 4826 (91%)were HCV-neg-
ative. We chose as many controls per case as possible, matching for age
(same ﬁve-year strata), sex, and HCV seropositivity. Finally, the control
group consisted of 232 HCV-positive controls (four controls per case)
and 1625 HCV-negative controls (65 controls per case). Therefore, we
identiﬁed 83 deaths due to HCC and 1857 age- and sex-matched
controls.
3.2. Comparison Between Cases and Controls at Baseline
The HCC cases and controls were well matched for age and sex in
both the HCV-positive and the HCV-negative groups (Table 1). The
mean age was 63.9 years in the HCC group and 64.8 years in the control
group. The HCC groupwasmore likely to smoke and drink than the con-
trols and to have histories of liver disease and diabetes mellitus. The
serum TGF-β1 concentrations were lower in the HCC group (26.5 ng/
mL) than in the control group (35.9 ng/mL; P b 0.001).
3.3. Association Between Serum TGF-β1 Concentration and the Risk of Inci-
dent HCC
Table 2 shows the relative risks for death fromHCC according to one
SD decrement of the TGF-β1 concentrations (7.9 ng/mL). Lower TGF-β1
concentrations were associated with a higher risk of death from HCC in
an unadjusted model; each SD decrement in the serum TGF-β1 concen-
tration was associated with a 2.6-fold increase in the risk of death from
Table 1
Baseline characteristics of 83 patients with fatal hepatocellular carcinoma and 1857
controls.
Participant characteristics Cases Controls P
(n= 83) (n=
1857)
Mean age, years 63.9 ±
6.4
64.8 ±
6.1
0.19
Men 54 (65) 1131 (61) 0.45
Mean serum TGF-β1, ng/mL 26.5 ±
9.5
35.9 ±
7.9
b0.0001
Smoking
Never smokers 25 (30) 869 (47) 0.003
Former smokers 14 (17) 324 (17) 0.89
Current smokers 36 (43) 572 (31) 0.02
Current drinking
Never drinkers 29 (35) 784 (42) 0.19
Former drinkers 14 (17) 74 (4) 0.003
Current drinkers 36 (43) 935 (50) 0.21
Mean ethanol intake among current
drinkers, g/day
12.8 ±
8.0
12.7 ±
9.2
0.98
History of diabetes mellitus 12 (14) 89 (5) 0.02
History of liver diseases 37 (45) 131 (7) b0.0001
Data are shown as n (%) unless otherwise stated.
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Fig. 1. Receiver operating curve (ROC) for the risk of hepatocellular carcinoma according
to the serum TGF-β1 concentration. The area under the ROC (AUC-ROC) for the serum
TGF-β1 concentrations was 0.78; the cut-off point was 30.0 ng/mL (sensitivity: 0.70;
speciﬁcity: 0.77). In the HCV-positive group, the AUC-ROC was 0.83; the cut-off point
was 29.3 ng/mL (sensitivity: 0.78; speciﬁcity: 0.75). In the HCV-negative group, the
AUC-ROC was 0.61; the cut-off point was undetermined.
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for the HCV-negative group. After adjusting for smoking, drinking
habits, and prior history of diabetes mellitus and liver disease, the ad-
justed RRs were 2.3 (95% CI: 1.7–3.0, P b 0.001) for the total subjects,
3.2 (95% CI: 2.1–5.0, P b 0.001) for the HCV-positive group, and 1.6
(95% CI: 1.0–2.3, P=0.03) for the HCV-negative group. There was a sig-
niﬁcant effect modiﬁcation by HCV status (interaction P = 0.02). The
sensitivity analysis restricting the patient population to those who sur-
vived for at least ﬁve years of follow-up showed similar results as the
main analysis (Table 2).
3.4. Predictive Value of TGF-β1 According to HCV-Positivity
The area under the receiver operating curve (AUC-ROC) for the
serum TGF-β1 concentration was 0.78 for predicting HCC-related
death. The cut-off point was 30.0 ng/mL with the sensitivity of 0.70
and the speciﬁcity of 0.77 (Fig. 1). In the HCV-positive group, the AUC-
ROC was 0.83 and the cut-off point was 29.3 ng/mL (sensitivity: 0.78;
speciﬁcity: 0.75). As for the HCV-negative group, the AUC-ROC was
0.61, and the cut-off point was undetermined.Table 2
Multivariate-adjusted relative risks (aRRs) and 95% conﬁdence intervals (CIs) of fatal he-
patocellular carcinoma cases according to 1-SD decrements in the serum TGF-β1
concentration.
All subjects HCV-positive HCV-negative
Total subjects
Cases n 83 58 25
Controls n 1857 232 1625
RR (95% CI, P value) 2.6 (2.1–3.4,
b0.0001)†
3.6 (2.4–5.2,
b0.0001)†
1.8 (1.2–2.7,
0.003)⁎
Multivariate aRR (95% CI, P
value)
2.3 (1.7–3.0,
b0.0001)†
3.2 (2.1–5.0,
b0.0001)†
1.6 (1.0–2.3,
0.03)⁎
Subjects who survived for at
least 5 years
Cases n 62 43 19
Controls n 1407 172 1235
RR (95% CI, P value) 2.7 (2.0–3.6,
b0.0001)†
4.3 (2.5–7.2,
b0.0001)†
1.6 (1.0–2.5,
0.05)
Multivariate aRR (95% CI, P
value)
2.3 (1.6–3.1,
b0.0001)†
3.6 (2.1–6.4,
b0.0001)†
1.4 (0.9–2.3,
0.17)
1-SD decrements in the serum TGF-β1 concentration = 7.9 ng/mL.
⁎ p b 0.05.
† p b 0.0001.4. Discussion
The ﬁndings of this nested case-controlled study using a large real-
world population-based dataset exhibited that low serum TGF-β1 con-
centrations predict death fromHCC, with a 160% increase in the risk per
one SD decrease in the TGF-β1 concentrations. This association
remained statistically signiﬁcant even after adjusting for confounding
factors and in a sensitivity analysis restricted to participants who sur-
vived for at least ﬁve years after the baseline survey, effectively elimi-
nating the possibility that these patients had undiagnosed HCC at the
baseline survey. Our data demonstrates that low levels of TGF-β1 can
identify patientswho are at higher risk of developingHCC. Furthermore,
the predictive value was signiﬁcantly higher among HCV-positive pa-
tients. TGF-β1 may be a serum predictor that becomes altered well be-
fore the development of clinically detectable malignancy.
Our ﬁndings are in agreement with the general theory that TGF-β1
works as a tumor suppressor during tumorigenesis. TGF-β1 is frequent-
ly present in the tumor microenvironment and prevents premalignant
progression during the beginning phases of carcinogenesis (Blobe et
al., 2000; Derynck et al., 2001; Ikushima and Miyazono, 2010;
Massagué et al., 2000). Many carcinomas have loss-of-function muta-
tions in the TGF-β1 pathway that involve its receptors or downstream
signal transducers such as SMADs (Tang et al., 2008). In terms of HCC,
an experimental study of human HCC tissue has shown that HCC
could arise from an IL-6-driven transformed stem cell with inactivated
TGF-β signaling (Yoshizawa, 2002), implying that TGF-β1 has a tumor
suppressor function. Therefore, it is reasonable to postulate that the
blood TGF-β1 concentrations may be decreased before the emergence
of HCC.
According to HCV status, we found a stronger association between
low TGF-β1 concentrations and the risk of death from HCC among the
HCV-positive group compared to the HCV-negative group, suggesting
that the predictive value of TGF-β1 is more potent in higher risk HCV-
positive individuals. This ﬁnding has important public health implica-
tions because this is the very patient population that consumes a large
amount of healthcare resources, and therefore the development of
strategies for early detection of HCC and prompt treatment is warrant-
ed. Our observations promote further investigation to assess whether
these high-risk individuals with HCV infection and low TGF-β1 concen-
trationswould beneﬁt frommore frequent surveillancewith abdominal
ultrasound and the measurement of biomarkers such as AFP, which are
standard procedures for the early HCC detection (Forner et al., 2012).
71Y. Watanabe et al. / EBioMedicine 12 (2016) 68–71The strengths of our study come from its large sample size and a
long-term follow-up in the general population in the natural setting.
The ten-year follow-up enabled us to perform sensitivity analysis in pa-
tients who survived at least for ﬁve years, for whom we could assume
that these patients did not have HCC at baseline given the high ﬁve-
yearmortality among patients with HCC. This was effective for ensuring
that we have collected blood samples to assess concentrations of serum
biomarkers prior to the development of malignancy. Additionally, with
the data on HCV seropositivity, we could examine associations between
serum TGF-β1 concentrations and HCCmortality stratiﬁed by HCV-pos-
itivity, revealing that the predictive value of TGF-β1 is higher in HCV-
positive patients. In contrast to the existing HCC biomarkers that be-
come altered after the development of HCC, our data shows that TGF-
β1 concentrations can be disturbed even in the absence of HCC, thereby
identifying high-risk patientswho aremore likely to develop HCC in the
future.
Our study has several limitations. Although our cohort study had a
large sample size, the number of HCC patients was limited because of
the low HCC mortality rate among the participants, especially for the
HCV-negative group. As only 25 of the 1650 HCV-negative participants
had HCC, the ROC curve in the HCV-negative group is less reliable. We
measured the serum TGF-β1 concentrations in the participants only
once, at the time of the baseline survey. Therefore, we did not monitor
chronological changes in the serum TGF-β1 concentrations in relation
to the HCCmortality rate. Although the self-administered questionnaire
completed at the time of the baseline survey asked the participants
whether they had any liver disease, we did not have any data regarding
the medical histories of speciﬁc diseases, such as hepatic cirrhosis.
In summary, our nested case-controlled study of 1940 participants
in the real-world setting without HCC at baseline displayed a strong as-
sociation between a low serum TGF-β1 concentration and a higher risk
of incidence HCC. The effect side was substantial and preserved
throughout different statistical assumptions and patient populations.
Our inferences indicate that serum TGF-β1 can distinguish between pa-
tients who are more likely to develop HCC from those with lower risk,
especially among HCV-positive patients. TGF-β1 may serve as the
serum biomarker that predicts the development of malignancy even
when clinically undetectable.
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